Lentivirus-Mediated Short Hairpin RNA for Follistatin Downregulation Suppresses Tumor Progression in Hypopharyngeal Carcinoma

Abstract

Objective

Follistatin (FST) inhibits the action of activin by interfering with the binding of activin to its receptor. Although the prognostic value of FST in various cancers has been investigated previously, studies rarely focused on hypopharyngeal carcinoma (HPC). In our study, the effect of FST expression on HPC tissues and cell lines was investigated.

Methods

A total of 60 patients with HPC were recruited for this study. Levels of FST mRNA and protein were measured by quantitative polymerase chain reaction (PCR) and immunohistochemistry in HPC tissue samples and by qPCR in the HPC FaDu cells, as well as immortal nasopharyngeal epithelial cell line NP-69 cells. After silencing the FST expression in FaDu cells using lentivirus-mediated siRNA that was specific for FST mRNA, cell proliferation was determined by a Celigo assay. Tumor growth was monitored in nude mice and viability was determined by a methylthiazoletetrazolium assay. The ratio of cell cycle arrest and apoptosis was evaluated by flow cytometry. The colony formation ability was performed using Giemsa staining. In addition, wound healing and Transwell migration and invasion assays were performed for the analysis of cell motility.

Results

FST expression was significantly higher in human HPC tissue and FaDu cells than in normal tissue and NP-69 cells. A higher expression of FST in HPC samples was positively correlated with advanced tumors. Moreover, FST knockdown by shRNA significantly decreased cell growth, colony formation, migration and invasion. Furthermore, FST silencing increased the cell apoptosis percentage, and arrested cell cycle in the S phase in FaDu cells. In addition, FST silencing suppressed tumor growth in vivo.

Conclusions

Our results indicated that the FST gene was associated with HPC progression and may serve as a potential therapeutic target for the treatment of HPC.

Keywords

follistatin / hypopharyngeal carcinoma / migration / invasion / proliferation / apoptosis

References

[1] GooiZ, FakhryC, GoldenbergD, et al.. AHNS Series: Do you know your guidelines? Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck, 2016, 38(7): 987-992

[2] YeLL, RaoJ, FanXW, et al.. Impact of tumor dimensions and lymph node density on the survival of patients with hypopharyngeal squamous cell carcinoma. Cancer Manag Res, 2018, 10: 4679-4688

[3] TianJ, LiuX, LiuX, et al.. Notch1 serves as a prognostic factor and regulates metastasis via regulating EGFR expression in hypopharyngeal squamous cell carcinoma. Onco Targets Ther, 2018, 11: 7395-7405

[4] HanY, ZhangM, ChenD, et al.. Downregulation of RNA binding motif protein 17 expression inhibits proliferation of hypopharyngeal carcinoma FaDu cells. Oncol Lett, 2018, 15(4): 5680-5684

[5] SepportaMV, TumminelloFM, FlandinaC, et al.. Follistatin as potential therapeutic target in prostate cancer. Target Oncol, 2013, 8(4): 215-223

[6] SuginoK, KurosawaN, NakamuraT, et al.. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem, 1993, 268(21): 15579-15587

[7] PhillipsDJ, De KretserDM. Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol, 1998, 19(4): 287-322

[8] ThompsonTB, LerchTF, CookRW, et al.. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell, 2005, 9(4): 535-543

[9] SebastianiG, DíazM, López-BermejoA, et al.. Circulating follistatin in the human foetus at term birth. Pediatr Obes, 2012, 7(1): 39-43

[10] WeltCK. The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Curr Opin Obstet Gynecol, 2002, 14(3): 317-323

[11] BartholinL, Maguer-SattaV, HayetteS, et al.. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene, 2002, 21(14): 2227-2235

[12] SinghR, BhasinS, BragaM, et al.. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology, 2009, 150(3): 1259-1268

[13] WintersSJ, GhoorayD, FujiiY, et al.. Transcriptional regulation of follistatin expression by GnRH in mouse gonadotroph cell lines: evidence for a role for cAMP signaling. Mol Cell Endocrinol, 2007, 271(1–2): 45-54

[14] NecelaBM, SuW, ThompsonEA. Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. J Biol Chem, 2008, 283(44): 29784-29794

[15] KangW, Saqui-SalcesM, ZavrosY, et al.. Induction of follistatin precedes gastric transformation in gastrin deficient mice. Biochem Biophys Res Commun, 2008, 376(3): 573-577

[16] EichbergerT, SanderV, SchnidarH, et al.. Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics, 2006, 87(5): 616-632

[17] HarkonenP, TornS, KurkelaR, et al.. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab, 2003, 88(2): 705-712

[18] RossmanithW, ChabicovskyM, Grasl-KrauppB, et al.. Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog, 2002, 35(1): 1-5

[19] van SchaikRH, WierikxCD, TimmermanMA, et al.. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer, 2000, 82(1): 112-117

[20] SimoneND, CrowleyWFJr, WangQF, et al.. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology, 1996, 137(2): 486-494

[21] ShikoneT, MatzukMM, PerlasE, et al.. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol, 1994, 8(8): 983-995

[22] SeachristDD, SizemoreST, JohnsonE, et al.. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Res, 2017, 19(1): 66

[23] ZabkiewiczC, ResaulJ, HargestR, et al.. Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival. Cancer Genomics Proteomics, 2017, 14(4): 241-251

[24] SchneiderCA, RasbandWS, EliceiriK W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 2012, 9(7): 671-675

[25] RenP, ChenFF, LiuHY, et al.. High serum levels of follistatin in patients with ovarian cancer. J Int Med Res, 2012, 40(3): 877-886

[26] TomodaT, NousoK, MiyaharaK, et al.. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol, 2013, 28(8): 1391-1396

[27] OginoH, YanoS, KakiuchiS, et al.. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res, 2008, 14(3): 660-667

[28] ZhangP, RuanY, XiaoJ, et al.. Association of serum follistatin levels with histological types and progression of tumor in human lung cancer. Cancer Cell Int, 2018, 18: 162

[29] TumminelloFM, BadalamentiG, FulfaroF, et al.. Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis, 2010, 27(8): 549-555

[30] LetoG, IncorvaiaL, FlandinaC, et al.. Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report. Cancer Invest, 2016, 34(9): 415-423

[31] BucherN, BrittenCD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer, 2008, 98(3): 523-528